Risk factors

Metagenomi Therapeutics (MGX) risk factors

Item 1A of every Metagenomi Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open MGX in Gloomberb →
  • FY2025 10-K risk factors

    88 risks, 4 new, 11 dropped, 20 reworded since the prior year. Tax exposure now highlights OBBBA and Section 174 treatment of research expenses, including potential cash-flow effects.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors

    95 risks. As an early-stage genome editing company with $248.3M in cash and a $223.0M accumulated deficit, risks center on unproven technology, substantial funding needs, and clinical trial execution.

    Filed Mar 17, 2025